Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Following its Senate counterparts, the Energy & Commerce health subcommittee on Thursday advanced a bill to reauthorize the user fee agreements over the next five years for drugs, generic drugs, medical devices and biosimilars.
All four amendments were agreed to, including one to increase generic drug competition and provide 180-day exclusivity for first generics where there’s a limited market, one on protecting the supply chain, one on improving the process for medical device inspections and one on over-the-counter hearing aids.
The Senate last week also agreed to amendments on OTC hearing aids, generics and device inspections.
A number of Democrats brought up the issue of drug prices while others noted the bipartisan nature of the user fee reauthorizations.
Rep. Jan Schakowsky (D-IL) said that the user fee bill advanced in the House does nothing to lower drug prices and she called on her counterparts across the aisle to hold hearings. A drug pricing hearing has been proposed in the Senate. Rep. Frank Pallone (D-NJ) also called for "serious policy discussions on reducing drug prices."
Tags: E&C, FDA user fees, user fee reauthorization